{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:08:42Z","timestamp":1779361722780,"version":"3.51.4"},"reference-count":41,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Risk &amp; Safety in Medicine"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Linezolid is one of the most used antibacterials to treat resistant gram-positive infections, though its use may result in a number of toxic effects, especially in the older adults. There is lack of data derived from the real-world studies regarding safety of linezolid in the elderly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>The aim<\/jats:title>\n                    <jats:p>To disclose the structure of adverse drug reactions (ADRs) associated with linezolid in patients \u226560\u00a0years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Retrospective analysis of spontaneous reports (SRs) from the Russian Pharmacovigilance database (April 2019\u2013December 2024).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SRs of patients \u226560\u00a0years accounted up to 19.9% in the total structure of SRs. Top-5 system-organ classes (SOCs) were blood and lymphatic system disorders (24.4%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 68), gastrointestinal disorders (17.6%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 49), investigations (11.1%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 31), skin and subcutaneous tissue disorders (9.7%, n = 27), and general disorders and administration site conditions (6.1%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 17). Top-5 preferred terms (PTs) were thrombocytopenia (7.9%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 22), anemia (7.2%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 20), nausea 4.3% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 12), diarrhea (3.6%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 10), vomiting (3.6%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 10), and leukopenia (3.6%,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 10).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Linezolid-induced myelosuppression was identified as the most significant safety concern in patients \u226560\u00a0years, underscoring the necessity for careful laboratory and clinical monitoring in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09246479251401400","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:59:12Z","timestamp":1763769552000},"page":"201-212","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety profile of linezolid in the elderly: National database analysis"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7729-2169","authenticated-orcid":false,"given":"Olga","family":"Butranova","sequence":"first","affiliation":[{"name":"Peoples\u2019 Friendship University of Russia"},{"name":"Named After Patrice Lumumba (RUDN)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8771-1983","authenticated-orcid":false,"given":"Victoria","family":"Koval","sequence":"additional","affiliation":[{"name":"Peoples\u2019 Friendship University of Russia"},{"name":"Named After Patrice Lumumba (RUDN)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Zyryanov","sequence":"additional","affiliation":[{"name":"Peoples\u2019 Friendship University of Russia"},{"name":"Named After Patrice Lumumba (RUDN)"},{"name":"State Budgetary Institution of Healthcare of the City of Moscow"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Asetskaya","sequence":"additional","affiliation":[{"name":"Peoples\u2019 Friendship University of Russia"},{"name":"Named After Patrice Lumumba (RUDN)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizaveta","family":"Terekhina","sequence":"additional","affiliation":[{"name":"Peoples\u2019 Friendship University of Russia"},{"name":"Named After Patrice Lumumba (RUDN)"},{"name":"Record and Analysis of Circulation of Medical Products Under the Federal Service for Surveillance in Healthcare"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitaly","family":"Polivanov","sequence":"additional","affiliation":[{"name":"Record and Analysis of Circulation of Medical Products Under the Federal Service for Surveillance in Healthcare"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Gorbacheva","sequence":"additional","affiliation":[{"name":"Peoples\u2019 Friendship University of Russia"},{"name":"Named After Patrice Lumumba (RUDN)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"4","key":"e_1_3_4_2_2","first-page":"1091","article-title":"Respiratory infections in the aging lung: implications for diagnosis, therapy, and prevention","volume":"14","author":"H\u00e4der A","year":"2023","unstructured":"H\u00e4der A, K\u00f6se-Vogel N, Schulz L, et al. Respiratory infections in the aging lung: implications for diagnosis, therapy, and prevention. Aging Dis 2023; 14(4): 1091\u20131104.","journal-title":"Aging Dis"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mucimm.2024.06.010"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-023-01233-7"},{"issue":"5","key":"e_1_3_4_5_2","first-page":"e83371","article-title":"Trends and disparities in pneumonia-related mortality in the U.S. population: a nationwide analysis using the CDC WONDER data","volume":"17","author":"Obianyo CM","year":"2025","unstructured":"Obianyo CM, Muoghalu N, Adjei EM, et al. Trends and disparities in pneumonia-related mortality in the U.S. population: a nationwide analysis using the CDC WONDER data. Cureus 2025; 17(5): e83371.","journal-title":"Cureus"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.12.658"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.36519\/idcm.2025.458"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000907"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S164515"},{"issue":"3","key":"e_1_3_4_10_2","first-page":"837","article-title":"Efficacy of linezolid on gram-positive bacterial infection in elderly patients and the risk factors associated with thrombocytopenia","volume":"29","author":"Bi LQ","year":"2013","unstructured":"Bi LQ, Zhou J, Huang M, et al. Efficacy of linezolid on gram-positive bacterial infection in elderly patients and the risk factors associated with thrombocytopenia. Pakistan J Med Sci 2013; 29(3): 837\u2013842.","journal-title":"Pakistan J Med Sci"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2022-003258"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10050530"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1310309"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1338902"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac485"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph16111575"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11061633"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae188"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac669"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01892-24"},{"key":"e_1_3_4_21_2","volume-title":"\u201cGood Pharmacovigilance Practice\u201d guideline","author":"Eurasian Economic Union","year":"2022","unstructured":"Eurasian Economic Union. \u201cGood Pharmacovigilance Practice\u201d guideline, 2022. https:\/\/docs.eaeunion.org\/docs\/ru-ru\/01433831\/err_09062022_81 (accessed 01 April 2025)."},{"key":"e_1_3_4_22_2","unstructured":"European Medicines Agency. \u201cICH E2B (R3) Electronic Transmission of Individual Case Safety Reports (ICSRs) \u2013 Data Elements and Message Specification \u2013 Implementation Guide \u2013 Scientific Guideline.\u201d European Medicines Agency 18 Dec. 2024 www.ema.europa.eu\/en\/ich-e2b-r3-electronic-transmission-individual-case-safety-reports-icsrs-data-elements-message (accessed 15 April 2025)."},{"key":"e_1_3_4_23_2","unstructured":"European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP) Module VI\u2014Collection Management and Submission of Reports of Suspected Adverse Reactions to Medicinal Products (Rev2). 2017. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf (accessed on 1 April 2025)."},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03542-z"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S408102"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v72i2.2883"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1292828"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6679076"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/20420986241279128"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13495"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13359"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2181160"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1515\/jbcpp-2020-0468"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad276"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2007.04.005"},{"issue":"10","key":"e_1_3_4_36_2","first-page":"e10890","article-title":"Reversible myelosuppresion with prolonged usage of linezolid in treatment of methicillin-resistant Staphylococcus aureus","volume":"12","author":"Sharma S","year":"2020","unstructured":"Sharma S, Syal A, Gupta M, et al. Reversible myelosuppresion with prolonged usage of linezolid in treatment of methicillin-resistant Staphylococcus aureus. Cureus 2020; 12(10): e10890.","journal-title":"Cureus"},{"key":"e_1_3_4_37_2","first-page":"325","article-title":"Linezolid toxicity and mitochondrial susceptibility: a novel neurological complication in a Lebanese patient","volume":"7","author":"Abou HOK","year":"2016","unstructured":"Abou HOK, Karnib M, El-Khoury R, et al. Linezolid toxicity and mitochondrial susceptibility: a novel neurological complication in a Lebanese patient. Front Pharmacol 2016; 7: 325.","journal-title":"Front Pharmacol"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01599-17"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00533-24"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-022-00628-9"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-77768-x"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.967311"}],"container-title":["International Journal of Risk &amp; Safety in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479251401400","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09246479251401400","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479251401400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:58:56Z","timestamp":1779361136000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09246479251401400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1177\/09246479251401400"],"URL":"https:\/\/doi.org\/10.1177\/09246479251401400","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/09246479251401400\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251401400\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251401400\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251401400\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251401400\/v2\/decision1","asserted-by":"object"}]},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"value":"0924-6479","type":"print"},{"value":"1878-6847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]}}}